Another phase I study (NCT02915445) in EpCAM+ recurrent or refractory nasopharyngeal carcinoma and breast cancer patients, and a phase I/II study (NCT03013712) for EpCAM-positive cancers (colon, esophageal, pancreatic, prostate, gastric, or hepatic carcinomas) are also ongoing, which indicates the great potential that CAR-T cell therapy can have in cancer treatment. Here, EPCAM is linked to nasopharyngeal carcinoma.